miR-17-92 overexpression in DLBCL enhances the pathogenic BCR signaling by the direct repression of protein tyrosine phosphatase, receptor type O (PTPRO) and PPP2CA gene products, and its inhibition increases the sensitivity to cytotoxic effects of BCR-inhibitors [189]. The gene discussed is BCR; the disease is diffuse large B-cell lymphoma.